Literature DB >> 33249059

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M Dreyling1, M Ghielmini2, S Rule3, G Salles4, M Ladetto5, S H Tonino6, K Herfarth7, J F Seymour8, M Jerkeman9.   

Abstract

Entities:  

Keywords:  antibody; chemotherapy; follicular lymphoma; lenalidomide; radiotherapy

Year:  2020        PMID： 33249059     DOI： 10.1016/j.annonc.2020.11.008

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  19 in total

Review 1.  Does MRD have a role in the management of iNHL?

Authors:  Ilaria Del Giudice; Irene Della Starza; Robin Foà
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Rituximab combined with GDP regimen can effectively improve the efficacy and immune function of non-Hodgkin lymphoma.

Authors:  Chao Song; Yanli Feng; Fanmei Ge; Zhiyun Zhang; Baoxiong Su
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

Review 3.  Time for an individualized approach to first-line management of follicular lymphoma.

Authors:  Guillaume Cartron; Judith Trotman
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 9.941

4.  Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials.

Authors:  Yucai Wang; Shouhao Zhou; Xinyue Qi; Fang Yang; Matthew J Maurer; Thomas M Habermann; Thomas E Witzig; Michael L Wang; Grzegorz S Nowakowski
Journal:  Blood Cancer J       Date:  2022-01-05       Impact factor: 9.812

Review 5.  Low-Grade Primary Splenic CD10-Positive Small B-Cell Lymphoma/Follicular Lymphoma.

Authors:  Rami Abdulbaki; Parastou Tizro; Victor E Nava; Maria Gomes da Silva; João L Ascensão
Journal:  Curr Oncol       Date:  2021-11-18       Impact factor: 3.677

6.  Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study.

Authors:  Mario Petrini; Gianluca Gaidano; Andrea Mengarelli; Ugo Consoli; Armando Santoro; Anna Maria Liberati; Marco Ladetto; Vincenzo Fraticelli; Attilio Guarini; Donato Mannina; Paola Ferrando; Paolo Corradini; Pellegrino Musto; Caterina Stelitano; Dario Marino; Andrea Camera; Marco Murineddu; Roberta Battistini; Giuseppe Caparrotti; Mauro Turrini; Luca Arcaini; Simone Santini; Manuela Cerqueti; Andres J M Ferreri; Nicola Cantore; Alessandro Inzoli; Giovanni Cardinale; Benedetto Ronci; Giorgio La Nasa; Stefano Massimi; Gianfranco Gaglione; Valentina Barbiero; Maurizio Martelli
Journal:  Adv Hematol       Date:  2022-01-27

7.  Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin's lymphoma: a monocenter analysis.

Authors:  I Hadi; A Schummer; M Dreyling; C Eze; R Bodensohn; O Roengvoraphoj; C Belka; M Li
Journal:  Sci Rep       Date:  2021-11-19       Impact factor: 4.379

8.  Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018.

Authors:  Manette A W Dinnessen; Otto Visser; Sanne H Tonino; Eduardus F M Posthuma; Nicole M A Blijlevens; Marie José Kersten; Pieternella J Lugtenburg; Avinash G Dinmohamed
Journal:  Blood Cancer J       Date:  2021-11-13       Impact factor: 11.037

9.  The Premalignant Ancestor Cell of t(14;18)+ Lymphoma.

Authors:  Gabriel Brisou; Bertrand Nadel; Sandrine Roulland
Journal:  Hemasphere       Date:  2021-06-01

10.  Low symptomatic COVID-19 in an elderly patient with follicular lymphoma treated with rituximab-based immunotherapy: A case report.

Authors:  Stanisław Łącki; Kinga Wyżgolik; Michał Nicze; Sylwia Georgiew-Nadziakiewicz; Jerzy Chudek; Kamil Wdowiak
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.